HMGN3 and liver cancer: HMGN3 is closely related to the occurrence of type 2 diabetes in humans and chemotherapeutic resistance in liver cancer (to vinblastine, topotecan, paclitaxel, adriamycin, etc.); thus, HMGN3 is a preventive target for type 2 diabetes (50) and can enhance the efficacy of chemotherapy in patients with liver cancer (51).